Trial Profile
Incidence of Microvascular Outcomes among Type 2 Diabetes Patients Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Cohort Study Using German Electronic Medical Records
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2016
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Sulfonylureas
- Indications Diabetic complications; Diabetic foot ulcer; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Sep 2016 Results assessing incidence of microvascular complications published in the Diabetes Therapy (2016).
- 28 Jul 2015 New trial record
- 09 Jul 2015 Primary endpoint has not been met. (Significantly lower incidence of diabetic foot ulcer with vildagliptin than with a sulfonylurea)